Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter Libby, M.D.

Co-Author

This page shows the publications co-authored by Peter Libby and Scott Kinlay.
Connection Strength

0.891
  1. Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study. Am Heart J. 2012 Apr; 163(4):735-40.
    View in: PubMed
    Score: 0.128
  2. Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study. Atherosclerosis. 2009 Oct; 206(2):551-5.
    View in: PubMed
    Score: 0.104
  3. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol. 2008 Jan; 28(1):142-7.
    View in: PubMed
    Score: 0.094
  4. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004 Jul 27; 110(4):386-91.
    View in: PubMed
    Score: 0.075
  5. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003 Sep 30; 108(13):1560-6.
    View in: PubMed
    Score: 0.071
  6. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation. 2002 Dec 03; 106(23):2888-93.
    View in: PubMed
    Score: 0.067
  7. Endothelial function and coronary artery disease. Curr Opin Lipidol. 2001 Aug; 12(4):383-9.
    View in: PubMed
    Score: 0.061
  8. Lipid lowering improves endothelial functions. Int J Cardiol. 2000 Jun 30; 74 Suppl 1:S3-S10.
    View in: PubMed
    Score: 0.057
  9. Inflammation, the endothelium, and the acute coronary syndromes. J Cardiovasc Pharmacol. 1998; 32 Suppl 3:S62-6.
    View in: PubMed
    Score: 0.048
  10. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol. 1996 Dec; 7(6):389-97.
    View in: PubMed
    Score: 0.044
  11. Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc. 2013 Jan 28; 2(1):e003103.
    View in: PubMed
    Score: 0.034
  12. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009 Jun 09; 53(23):2186-96.
    View in: PubMed
    Score: 0.026
  13. Improved characterization of atherosclerotic plaques by gadolinium contrast during intravascular magnetic resonance imaging of human arteries. Atherosclerosis. 2008 Feb; 196(2):919-25.
    View in: PubMed
    Score: 0.023
  14. Characterization of human atherosclerotic plaques by intravascular magnetic resonance imaging. Circulation. 2005 Oct 11; 112(15):2324-31.
    View in: PubMed
    Score: 0.020
  15. Thoughts on the role of the healing professions and the events of September 11, 2001. Circulation. 2002 Mar 26; 105(12):1509-10.
    View in: PubMed
    Score: 0.016
  16. Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. Am J Cardiol. 1997 Mar 06; 79(5A):17-23.
    View in: PubMed
    Score: 0.011
  17. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation. 1997 Jan 07; 95(1):5-7.
    View in: PubMed
    Score: 0.011
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.